A test to predict the spread of clear cell kidney cancer
Official title: A PROGNOSTIC ASSAY FOR METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Funded at Lagrange Scientific, LLC · NIH-10931950 · Data updated 2026-11-12
This study is looking to find certain markers in kidney cancer tissues that can help doctors predict which patients might experience faster disease progression, so they can start treatment sooner for those who need it most.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lagrange Scientific, LLC NIH-funded |
| Lab location | 1 site (Pewee Valley, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $927,997 |
| NIH project number | 1R44CA288032-01A1 |
| Project ID | NIH-10931950 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma who are at risk of metastasis.
✕Less likely to help
Patients with non-clear cell types of renal carcinoma or those who are not diagnosed with renal cancer may not benefit from this research.
What this research studies
This research aims to develop a prognostic assay that identifies specific biomarkers in clear cell renal cell carcinoma (ccRCC) tissues. By analyzing these biomarkers, the study seeks to predict which patients are at risk of early disease progression to metastasis. This could allow for earlier intervention with systemic therapies, rather than waiting for significant recurrence. The goal is to improve patient outcomes by stratifying those who need aggressive treatment from those who can safely adopt a more conservative management approach.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more effective treatment options for patients with aggressive forms of kidney cancer.
How similar studies have gone: Previous research has shown promise in using biomarker panels for cancer prognosis, indicating potential success for this novel approach.
Where this research is happening
-
Lagrange Scientific, LLC
Pewee Valley, United States Active
Researchers
- Principal investigator: Coughlin, Richard Thomas — Lagrange Scientific, LLC
- Study coordinator: Coughlin, Richard Thomas
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.